Ally Bridge Group »

Taysha Gene Therapies shares owned by Ally Bridge Group

Quarter-by-quarter ownership of Taysha Gene Therapies (TSHA) shares owned by Ally Bridge Group from 13F filings

Historical chart of Ally Bridge Group investment in Taysha Gene Therapies

Tip: Access up to 7 years of quarterly data

All positions including Taysha Gene Therapies held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Taysha Gene Therapies by Ally Bridge Group

Quarter filed Position value Share count Share price at filing
2025-09-30 $6.2M 1.9M 3.27

More positions owned by Ally Bridge Group

Soleno Therapeutics (SLNO)
Replimune Group Call Option (REPL)
Madrigal Pharmaceuticals (MDGL)
Compass Pathways Sponsored Ads (CMPS)
Atai Beckley Nv SHS (ATAI)
Ascendis Pharma A/s - Sponsored Adr (ASND)
Lenz Therapeutics (LENZ)
Taysha Gene Therapies Com Shs (TSHA)
Amylyx Pharmaceuticals (AMLX)
Eupraxia Pharmaceuticals (EPRX)
Praxis Precision Medicines I Com New Call Option (PRAX)
Monopar Therapeutics Com New (MNPR)
Arcutis Biotherapeutics (ARQT)
Mind Medicine Mindmed Com New (MNMD)
Tarsus Pharmaceuticals (TARS)

View all positions for Ally Bridge Group

Top funds holding Taysha Gene Therapies

Rtw Investments
RA Capital Management
venBio Select Advisor
Morgan Stanley
BlackRock
FMR
Goldman Sachs Group
Vanguard Group
Siren
Octagon Capital Advisors
Point72 Asset Management
State Street Corporation
Vestal Point Capital
Deerfield Management Company
Polar Capital Holdings

View all funds holding Taysha Gene Therapies